A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma

NRAS mutations are the most common alterations among RAS isoforms in cutaneous melanoma, with patients harboring these aggressive tumors having a poor prognosis and low survival rate. The main line of treatment for these patients is MAPK pathway‐targeted therapies, such as MEK inhibitors, but, unfor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pigment Cell Melanoma Res
Main Authors: Nagler, Adi, Vredevoogd, David W., Alon, Michal, Cheng, Phil F., Trabish, Sophie, Kalaora, Shelly, Arafeh, Rand, Goldin, Victoria, Levesque, Mitchell P., Peeper, Daniel S., Samuels, Yardena
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7383499/
https://ncbi.nlm.nih.gov/pubmed/31549767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12825
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados